| Date Filed | Type | Description |
| 09/27/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 08/21/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 08/18/2023 |
8-K
| Quarterly results |
| 08/15/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 08/14/2023 |
8-K
| Entry into a Material Definitive Agreement Interactive Data |
| 08/08/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/08/2023 |
8-K
| Quarterly results |
| 05/31/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 05/24/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 05/09/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 05/09/2023 |
8-K
| Quarterly results |
| 04/18/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 04/18/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 04/17/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 02/28/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
| 02/28/2023 |
8-K
| Quarterly results |
| 02/14/2023 |
SC 13G/A
| Point72 Asset Management, L.P. reports a 1.9% stake in Arcutis Biotherapeutics, Inc. |
| 02/09/2023 |
SC 13G/A
| FMR LLC reports a 15% stake in ARCUTIS BIOTHERAPEUTICS INC |
| 02/08/2023 |
SC 13G
| STATE STREET CORP reports a 6% stake in INITIAL FILING ARCUTIS BIOTHERAPEUTICS INC |
| 02/03/2023 |
SC 13G/A
| BlackRock Inc. reports a 8.6% stake in ARCUTIS BIOTHERAPEUTICS INC |
| 12/16/2022 |
8-K
| Quarterly results |
| 11/08/2022 |
10-Q
| Quarterly Report for the period ended September 30, 2022 |
| 11/08/2022 |
8-K
| Quarterly results |
| 09/07/2022 |
8-K
| Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S... |
| 08/26/2022 |
SC 13D/A
| ORBIMED ADVISORS LLC reports a 4.7% stake in Arcutis Biotherapeutics, Inc. |
| 08/09/2022 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
| 08/08/2022 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
| 08/08/2022 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
| 08/05/2022 |
8-K
| Quarterly results |
| 08/04/2022 |
10-Q
| Quarterly Report for the period ended June 30, 2022 |
| 08/04/2022 |
8-K
| Quarterly results |
| 08/04/2022 |
424B5
| Form 424B5 - Prospectus [Rule 424(b)(5)]: |
| 08/02/2022 |
424B5
| Form 424B5 - Prospectus [Rule 424(b)(5)]: |
| 08/02/2022 |
8-K
| Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Other Even... |
|